Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Prophylaxis

Prophylaxis

23

Pipeline Programs↗

30

Active Trials↗

25

Companies Involved↗

Prophylaxis is an emerging landscape with 23 programs across 25 companies. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

22/100

Mech. Concentration

14/100

Completion Rate

82/100

Attrition Rate

13/100

Pipeline

Programs by Phase

Preclinical7

Carvedilol+vsl#3

Institute of Liver and Biliary Sciences, India

Doxycycline Hyclate

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Infasurf

Roberta Ballard

Combigan

EMS

Truvada

Gilead

Phase 1

No programs

Phase 25

Sirolimus

Prism Pharmaceuticals

Cyclophosphamide

Baxter Healthcare Corporation

Abatacept

Bristol-Myers Squibb

Sorafenib

Bayer

Anti-Thymocyte Globulin

Novartis

Phase 311

Ervebo

ANRS, Emerging Infectious Diseases

Inmazeb

Regeneron

Cabotegravir

GSK

Letermovir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Dalteparin Sodium

Pfizer

Approved

No programs

Analysis

Modality Breakdown

95%

Small molecule

20 of 21 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

224

clinical trials

Completed136 · 61%

Unknown status28 · 13%

Recruiting19 · 8%

Terminated17 · 8%

Withdrawn13 · 6%

Not yet recruiting6 · 3%

Other5 · 2%

Clinical Trials

Trial Activity

224 trials

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06532084·88 enrolled

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Recruiting·—·N/A·NCT06441669·60 enrolled

Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04292054·506 enrolled

The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.

Recruiting·BBangrak STIs Center·Phase 4·NCT07397403·400 enrolled

Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)

Recruiting·—·N/A·NCT04762134·560 enrolled

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

Recruiting·Evandro Chagas National Institute of Infectious Disease·Phase 3·NCT05515770·1,200 enrolled

Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters

Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT05029063·1,828 enrolled

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

Recruiting·MMonash University·Phase 4·NCT05447559·9,180 enrolled

Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding

Recruiting·—·Phase 2/3·NCT04499898·306 enrolled

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Recruiting·MMassachusetts General Hospital·Phase 4·NCT07199335·100 enrolled

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

Recruiting·YYale University·Phase 2/3·NCT04924322·258 enrolled

Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT

Recruiting·PPeking University People's Hospital·Phase 2·NCT06984536·40 enrolled

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT06812598·330 enrolled

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures

Recruiting·WWake Forest University Health Sciences·Phase 4·NCT05851898·100 enrolled

Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)